Response was assessed after completion of induction chemotherapy, with chest and upper abdominal CT scan. Brain, chest, and abdominal CT scans were repeated at completion of chemoradiation therapy, ...

For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...

Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence. Our NLP ...

Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer. Adjuvant icotinib of 12 months versus observation ...

PTNB before surgery in stage 1 NSCLC patients is linked to higher local-regional recurrence and mortality rates. The study included 2026 patients, with 38.6% undergoing PTNB, showing higher recurrence ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.